Drugs / LV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04731467 Background | Mar 2021 → Sep 2024 | colorectal adenocarcinoma, malignant pancreatic neoplasm, melanoma, non-small cell lung carcinoma +2 | Famewave Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04731467 ↗ |
| Route | Intravenous | “CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.” NCT04731467 ↗ |